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Abstract 1 
Currently, no reliable predictors of cognitive impairment in Parkinson’s disease exist. We 2 
hypothesised that microstructural changes at grey matter T1-weighted MRI and diffusion 3 
tensor imaging in the cholinergic system nuclei and associated limbic pathways underline 4 
cognitive impairment in Parkinson’s disease. We performed a cross-sectional comparison 5 
between Parkinson’s disease patients with and without cognitive impairment. We also 6 
performed a longitudinal 36-month follow up study of cognitively intact Parkinson’s patients, 7 
comparing patients who remained cognitively intact to those who developed cognitive 8 
impairment. Parkinson’s disease patients with cognitive impairment showed lower grey 9 
matter volume and increased mean diffusivity in the nucleus basalis of Meynert, compared to 10 
Parkinson’s disease patients without cognitive impairment.  These results were confirmed 11 
both with region-of-interest and voxel-based analyses, and after partial volume correction. 12 
Lower grey matter volume and increased mean diffusivity in the nucleus basalis of Meynert 13 
was predictive for developing cognitive impairment in cognitively intact patients with 14 
Parkinson’s disease, independent of other clinical and non-clinical markers of the disease. 15 
Structural and microstructural alterations in entorhinal cortex, amygdala, hippocampus, 16 
insula, and thalamus were not predictive for developing cognitive impairment in Parkinson’s 17 
disease. Our findings provide evidence that degeneration of the nucleus basalis of Meynert 18 
precedes and predicts the onset of cognitive impairment, and might be used in clinical setting 19 
as reliable biomarker to stratify patients at higher risk of cognitive decline. 20 
 21 
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 3 
Introduction 1 
When James Parkinson first described the “shaking palsy” in 1871, he assumed that “the 2 
senses and intellect were uninjured” (Parkinson, 1817). Unfortunately, this claim was not 3 
fully accurate (Saeed et al., 2017). Cognitive impairment is highly prevalent in Parkinson’s 4 
disease, and approximately 80% of Parkinson’s disease patients will eventually develop 5 
dementia during the course of their illness (Hely et al., 2008). Cognitive impairment is one of 6 
the most clinically relevant symptoms in Parkinson’s disease (Aarsland et al., 2012) and 7 
causes an increased risk of mortality and significant reduction in quality of life (Forsaa et al., 8 
2010; Winter et al., 2011). 9 
 10 
The mechanisms underlying the development of cognitive impairment in Parkinson’s disease 11 
remain unclear. Several imaging and clinical markers have been evaluated over the past years 12 
as potential predictors for the development of cognitive impairment in Parkinson’s disease 13 
(Moore and Barker, 2014; Xu et al., 2016). Clinical markers for predicting cognitive 14 
impairment in Parkinson’s disease vary across studies with contradicting evidence. 15 
Depression, REM sleep behaviour disorder (Aarsland et al., 2003; Zhu et al., 2014) gait 16 
dysfunction, cerebrovascular diseases associated with white matter lesions (Ma et al., 2015),  17 
olfactory dysfunction, Apo-E genotype, and the ratio CSF Amyloid-β:Tau (Schrag et al., 18 
2017) have been suggested as predictors for the development of cognitive impairment in 19 
Parkinson’s disease (Aarsland et al., 2003), however, several of these have been disputed 20 
(Zhu et al., 2014). Imaging studies have shown cortical and subcortical brain regions to be 21 
predictive of cognitive impairment in Parkinson’s disease, including structural and 22 
microstructural changes within the entorhinal cortex, amygdala, hippocampus, insula, 23 
thalamus, striatum and tempo-parieto-frontal areas (Hattori et al., 2012; Melzer et al., 2012). 24 
 4 
However, evidence from these studies are limited due to small sample sizes, caveats in study 1 
designs, classification of cognitive impairment, and subject inclusion criteria. 2 
 3 
Loss of cholinergic innervation of the cerebral cortex has been suggested as one mechanism 4 
of dementia (Aarsland et al., 2017) and pathological changes seen in Parkinson’s disease 5 
patients with cognitive impairment support this theory. In the basal forebrain, extra-nigral 6 
Lewy bodies are present in neurons of the nucleus basalis of Meynert, the primary source of 7 
cholinergic innervation of the cerebral cortex (Bohnen and Albin, 2011a). Braak et al. 8 
suggests this cholinergic neuron degeneration occurs at the same stage as nigral pathology 9 
(Braak et al., 2003). Imaging studies have demonstrated structural and microstructural 10 
changes within the nucleus basalis of Meynert to be predictive of cognitive impairment (Lee 11 
et al., 2014; Schmitz and Nathan Spreng, 2016). Significant loss of cholinergic neurons in the 12 
nucleus basalis of Meynert has been observed in Parkinson’s disease in the absence of 13 
Alzheimer’s disease pathology (Rogers et al., 1985), and positron emission tomography 14 
imaging studies have confirmed that cholinergic neurons in the basal forebrain degenerates at 15 
early stages of Parkinson’s disease. This degeneration progresses with the onset of cognitive 16 
impairment (Bohnen and Albin, 2011a). Lower levels of choline acetyltransferase and 17 
acetylcholinesterase have also been associated with cognitive impairment in Parkinson’s 18 
disease, at similar levels as seen in Alzheimer’s disease (Bohnen et al., 2003). Currently, no 19 
robust predictors of cognitive impairment are validated and used in clinical practice. 20 
 21 
Here, we hypothesised that structural and microstructural changes in the cholinergic system 22 
nuclei and associated limbic pathways could be underlying cognitive impairment in patients 23 
with Parkinson’s disease, and moreover could predict the development of cognitive 24 
impairment. We sought to investigate this hypothesis by performing a cross-sectional 25 
 5 
baseline comparison of MRI data between Parkinson’s disease patients with and without 1 
cognitive impairment, and a longitudinal 36-month comparison of MRI data between those 2 
Parkinson’s patients who remained cognitively intact and those who developed cognitive 3 
impairment (Figure 1).  4 
 5 
Methods 6 
Study participants. Data used for this paper were obtained from the Parkinson’s 7 
Progression Marker Initiative (PPMI) database (www.ppmi-info.org/data) in January 2017. 8 
We have excluded subjects with a history of stroke or transient ischemic attack. A total of 9 
304 Parkinson’s disease patients not on Parkinson’s medications (drug-naïve) and 167 heathy 10 
controls were identified. All patients underwent an initial screening visit followed by a 11 
baseline visit where demographics, family history, clinical characteristics, cognitive status 12 
and non-motor symptoms measurements were collected (Supplementary Methods). 13 
 14 
Cognitive assessments. Cognitive status was assessed at baseline and follow-up visits 15 
every 6 months (terminated at 36 months, or earlier if a patient developed cognitive 16 
impairment). Cognitive function was defined as two levels. Level 1 diagnosis was done on all 17 
patients at baseline and was determined based on MoCA scores. Patients with MoCA ≥26 18 
were screened as cognitively normal (PD-MoCA≥26; n=232), and patients with MoCA ≤25 19 
were screened as with cognitive impairment (PD-MoCA≤25; n=72). Level 2 diagnosis was 20 
determined at follow-up visits with MoCA≤25, self-reported issues in cognitive function, and 21 
at least two cognitive test scores (irrespective of test domain) greater than 1.5 standard 22 
deviations (SD) below mean healthy control age/education standardized scores as published 23 
previously (Weintraub et al., 2015). At the end of the 36-month period, 35 Parkinson’s 24 
patients satisfied Level 2 diagnosis for cognitive impairment, whereas 197 patients did not .  25 
 6 
 1 
Image acquisition and processing. T1weighted (T1-MRI) and T2-weighted MRI (T2-2 
MRI) images were acquired by Philips, GE, or SIEMENS machines with either 1.5T or 3T 3 
strength. Diffusion tensor imaging images were obtained with SIEMENS machines using a 4 
2D single-shot echo planar imaging sequence with 3T strength (Supplementary Methods). 5 
T1-MRI images were pre-processed using Statistical Parametric Mapping 12 (SPM, 6 
Wellcome Trust Centre for Neuroimaging, London, UK) implemented in MATLAB (The 7 
Math-Works, Natick, MA, USA) to allow for grey matter voxel based morphometry analysis. 8 
Images were segmented and modulated into grey matter, white matter, CSF, bone and soft 9 
tissue. The grey matter image was smoothened, to cope with functional anatomical 10 
variability, and normalized and aligned into Montreal Neurological Institute (MNI) space. 11 
The final T1-MRI image map represents the volume of grey matter within each voxel. T2-12 
MRI images were co-registered with T1-MRI for each subject to rule out vascular pathology 13 
and quantify the volume of white matter lesions. 14 
 15 
Diffusion weighting was isotropically distributed along 64 gradient directions with a b-value 16 
of 1000s/mm2, and a non-diffusion-weighted imaging (b0) was acquired at the start of each 17 
scan. Diffusion data analysis was performed with FSL Diffusion Toolbox (FDT) (FMRIB 18 
Software Library (FSL), Centre Software Library, University of Oxford, Oxford, UK); topup 19 
(Andersson et al., 2003) and eddycorrect (Andersson and Sotiropoulos, 2016) corrected for 20 
head motion, artefacts and eddy currents. DTIFit fitted diffusor tensor model maps at each 21 
voxel to generate fractional anisotropy maps, and mean diffusivity maps (Supplementary 22 
Methods).  23 
 24 
 7 
Grey matter analysis was done by T1-MRI images obtained from all patients described 1 
(Figure 1A). Diffusion tensor imaging analysis was done on a subset of 62 healthy control 2 
and 84 Parkinson’s disease patients (Figure 1B). Of the Parkinson’s disease patients, 64 were 3 
screened as not cognitively impaired at baseline (PD-MoCA≥26) and 20 were screened as 4 
cognitively impaired at baseline (PD-MoCA≤25). Patients not cognitively impaired at 5 
baseline screening were followed up for the same period: 17 Parkinson’s disease patients 6 
satisfied Level 2 diagnosis for cognitive impairment, whereas 47 patients did not. 7 
 8 
To account for the variability across MRI scanners, we investigated differences in grey matter 9 
mean voxel values obtained by different MRI manufacturers (Philips vs. GE. vs. SIEMENS) 10 
and with different strength of field (1.5 vs. 3T). We also investigated differences in diffusion 11 
tensor imaging mean diffusivity mean voxel values obtained with different protocols (gated 12 
vs. non-gated). Considering that the variability in diffusion tensor imaging across cameras is 13 
usually high, we investigated the cross-centre variance of mean diffusivity mean voxel 14 
values. 15 
 16 
Regions-of-interest analysis. Regions-of-interest were identified using probabilistic 17 
anatomical maps available in SPM Anatomy Toolbox (Eickhoff et al., 2005). Probabilistic 18 
anatomical maps were created from microscopic histological post-mortem analysis of ten 19 
brains. Each map describes the anatomical probability of finding the regions-of-interest at 20 
each voxel in MNI reference space, based on the relative frequency of finding the areas in the 21 
same space in the ten-brain analysis. Based on the probability maps, each voxel was assigned 22 
to the most probably area by applying an algorithm to the probabilistic anatomical maps 23 
available in the toolbox, previously described (Eickhoff et al., 2005) (Figure 2). The nucleus 24 
basalis of Meynert is located in the basal forebrain, which is composed of cholinergic cell 25 
 8 
groups defined histologically as Ch1-Ch6. Ch4 corresponds to the nucleus basalis of Meynert  1 
(Mesulam et al., 1983), and was identified using an existing available probabilistic 2 
anatomical map (Zaborszky et al., 2008). Similarly, the entorhinal cortex, amygdala, 3 
hippocampus, and insula were identified using existing available probabilistic anatomical 4 
maps (Kurth et al., 2010). The thalamus was identified using the Thalamic Connectivity atlas 5 
by Behrens (Behrens et al., 2003). A reference region was identified as the primary 6 
somatosensory cortex area 3a through existing available probabilistic anatomical maps (Choi 7 
et al., 2006). This area confirmed anatomical findings, as the primary somatosensory cortex 8 
is relatively unaffected in Parkinson’s disease and dementia pathology (Burton et al., 2004). 9 
Regions-of-interest analysis was performed on normalized MNI space images and repeated 10 
on co-registered T1-MRI applying the partial volume correction (Zhang et al., 2016). 11 
Potential artefacts due to partial volume were reduced by extracting regions-of-interests in 12 
diffusion tensor imaging conditioned on brain tissue content derived from the corresponding 13 
segmented structural MRI data. Specifically, to reduce artefacts due to brain atrophy, the 14 
regions-of-interests were extracted from regions with more than 90% probability of brain 15 
tissue content. To further reduce artefacts to partial brain tissue volume, a threshold of more 16 
than 50% probability of grey matter content was applied for regions-of-interests in grey 17 
matter areas, as previously done in other PPMI studies (Zhang et al., 2016). 18 
 19 
Voxel-based analysis. Voxel-wise statistics for between-group comparisons were 20 
computed using appropriately weighted contrasts to localize significant changes in mean 21 
voxel values on voxel based morphometry and diffusion tensor imaging fractional anisotropy 22 
and mean diffusivity MNI images. The contrasts were used to derive Z-scores on a voxel 23 
basis using the general linear model. The threshold for statistical significance was set to 24 
 9 
P<0.001 (uncorrected). Voxel-based analysis was performed using SPM12 implemented in 1 
Matlab 8.4. 2 
 3 
White matter lesion volume. Quantification of white matter lesions was performed by 4 
using T1-MRI and T2/FLAIR MRI (Leritz et al., 2014). White matter lesions volumes in T1-5 
MRI were calculated with the Freesurfer image analysis suite 6 
(http://surfer.nmr.mgh.harvard.edu/), as described previously (Fischl et al., 2002; Fischl et 7 
al., 2004). Each subject’s T1-MRI lesion mask was overlaid on co-registered T2/FLAIR 8 
images for quality control on final volumetric data (Supplementary Methods). In details, the 9 
volumetric T1-MRI images were processed to remove non-brain tissue using a hybrid 10 
watershed/surface deformation procedure (Segonne et al., 2004), automated Talairach 11 
transformation, and segmentation of the subcortical white matter and deep gray matter 12 
volumetric structures (Fischl et al., 2002; Fischl et al., 2004). White matter lesions were 13 
labelled using a probabilistic procedure (Fischl et al., 2002). Total white matter lesions 14 
(hypointensity) volume was then calculated for each hemisphere; these were averaged 15 
together to create a single white matter lesions volume for each subject. A manual quality 16 
check of the output of the Freesurfer analysis, for each individual MRI, was performed with 17 
the freeview software and lesions volume amended accordingly (G.P., J.B.). White matter 18 
lesions T1-hypointensity to be labelled in a more restricted portion of tissue compared to 19 
hyperintensity volumes measured on T2/FLAIR (Salat et al., 2010). To reduce this bias, 20 
quality control was performed on final volumetric data by overlaying each subject's lesion 21 
map on the T2/FLAIR image (J.S., G.P.). None of the lesion masks had errors that would 22 
require exclusion. There were minor errors, particularly in the determination of the 23 
boundaries of large lesions. However, we did not prefer to correct them manually, as the 24 
 10 
intra-rater and inter-rater variability associated with manual delineations could potentially 1 
bias the results. 2 
Statistical analysis. Statistical analysis was performed in Statistical Package for Social 3 
Sciences (SPSS 23.0) software (SPSS Inc., Chicago, IL). Normality was tested with the 4 
Shapiro-Wilk test (<50 values) or Kolmogorov-Smirnov test (≥50 values), as appropriate. 5 
Continuous variables were expressed as mean and standard deviations in parentheses and 6 
compared using independent samples T-Test (normally distributed) and exact Mann-Whitney 7 
U test (not normally distributed). Multivariate analysis of variance (MANOVA) was used to 8 
assess the main effects of regional structural and microstructural changes among the groups. 9 
If the overall multivariate test was significant, P-values for each variable were calculated 10 
following Bonferroni’s multiple comparisons test. Subsequently, MANOVA was repeated 11 
adding age as covariate. Categorical variables were expressed as proportions and compared 12 
using Fisher’s test. To determine predictors of cognitive decline, Cox survival proportional 13 
hazards analyses were performed using each regions-of-interest as a predictor of cognitive 14 
impairment at univariate analysis. Multivariate Cox survival analyses were carried out 15 
including each significant regions-of-interest at univariate and, as covariates, clinical and 16 
non-clinical predictors of cognitive impairment previously validated in the PPMI study by 17 
Schrag et al. (2017). The analyses have been also repeated including as covariates in the 18 
model: age, white matter lesions volume and presence of axial motor symptoms. The first 19 
occurrence of cognitive impairment at follow up was used as for the time-to-event in the Cox 20 
model. To increase stability of our findings, we confirmed that the outcome present at one 21 
visit was still present at the subsequent visits. Grey matter mean voxel values were increased 22 
by a factor 100, while fractional anisotropy and mean diffusivity diffusion tensor imaging 23 
mean voxel values were increased by a factor 1000 in Cox survival analysis. Kaplan–Meier 24 
survival estimates were generated after stratifying Parkinson’s disease patients by abnormal 25 
 11 
regions-of-interest mean voxel values compared using log-rank (Mantel Cox) test. Abnormal 1 
regions-of-interest mean voxel was defined as 1 SD from our population of healthy controls. 2 
A P value of less than 0.05 was used as the cut-off point to be determined a statistically 3 
significant result. 4 
 5 
Data availability. All data used in this study is available from PPMI database (www.ppmi-6 
info.org/data).  7 
 8 
Results  9 
Grey matter changes and cognitive impairment in Parkinson’s disease patients. A 10 
total of 304 Parkinson’s disease patients were identified to be included in this study (Table 1).  11 
We first conducted a cross-sectional comparison of grey matter mean voxel values between 12 
healthy controls and Parkinson’s disease patients at baseline. No differences were found for 13 
the nucleus basalis of Meynert, entorhinal cortex, amygdala, hippocampus, insula, thalamus, 14 
or primary somatosensory cortex (reference region). After partial volume correction, no 15 
differences were found in any regions-of-interest (Table 2). Then, we stratified Parkinson’s 16 
disease patients into two subgroups: screened as cognitively normal (PD-MoCA≥26, n=232) 17 
and screened as cognitively impaired (PD-MoCA≤25, n=72). We found lower grey matter 18 
mean voxel values of nucleus basalis of Meynert (P=0.016), amygdala (P=0.022) and 19 
thalamus (P=0.001) in cognitively impaired vs. cognitively normal Parkinson’s disease 20 
patients. No differences were found for other regions-of-interests and the results were 21 
consistent when covariate for age. After partial volume correction, we found lower grey 22 
matter mean voxel values of nucleus basalis of Meynert (P=0.01) and thalamus (P<0.001) 23 
but no differences in the amygdala or other areas (Figure 3A-C, Table 3). 24 
 12 
 1 
Regions-of-interest-analysis was repeated at voxel-based level and confirmed these results. 2 
Statistical parametric maps showed a reduction in grey matter at full brain voxel-based 3 
analysis in cognitively impaired compared to cognitively normal Parkinson’s disease patients 4 
(Supplementary Table 1, Figure 4A). 5 
 6 
Microstructural changes and cognitive impairment in Parkinson’s disease 7 
patients. We conducted a cross-sectional comparison of diffusion tensor imaging fractional 8 
anisotropy and mean diffusivity mean voxel values between heathy controls and Parkinson’s 9 
disease patients on a priori regions-of-interest selection at baseline. We found no differences 10 
in any fractional anisotropy or mean diffusivity regions-of-interest mean voxel values. These 11 
results were confirmed at voxel-based level and after partial volume correction, which 12 
showed no differences in any areas (Table 2). Then, we stratified Parkinson’s disease patients 13 
into two subgroups: screened as cognitively normal (PD-MoCA≥26, n=64) and screened as 14 
cognitively impaired (PD-MoCA≤25, n=20). We found increased mean diffusivity mean 15 
voxel values of nucleus basalis of Meynert (P=0.03), entorhinal cortex (P=0.02), insula 16 
(P=0.02), and thalamus (P=0.04) in cognitively impaired vs. cognitively normal Parkinson’s 17 
disease patients. No differences were found for other areas. After partial volume correction, 18 
we found higher mean diffusivity mean voxel values of the nucleus basalis of Meynert 19 
(P=0.045), entorhinal cortex (P=0.002), amygdala (P=0.020), hippocampus (P<0.001), and 20 
thalamus (P=0.001) in cognitively impaired vs. cognitively normal Parkinson’s disease 21 
patients. We also found lower fractional anisotropy mean voxel values of the amygdala 22 
(P=0.033), hippocampus (P=0.033), and thalamus (P=0.005) in cognitively impaired vs. 23 
cognitively normal Parkinson’s disease patients (Figure 3D-G, Table 3).  24 
 25 
 13 
Regions-of-interest-analysis was repeated at voxel-based level and confirmed these results. 1 
Statistical parametric maps showed increased in mean diffusivity at voxel-based analysis in 2 
cognitively impaired compared to cognitively normal Parkinson’s disease patients 3 
(Supplementary Table 1, Figure 4B). 4 
 5 
Grey matter changes as predictors of Parkinson’s disease cognitive decline. At 6 
multivariate Cox survival analysis of regions-of-interests and age as a co-variate, the nucleus 7 
basalis of Meynert grey matter mean voxel value was the only statistically significant 8 
predictor of developing cognitive impairment (positive Level 2 diagnosis) in Parkinson’s 9 
disease: [HR]: 0.908, [C.I.]: 0.843–0.978, Wald: 12.067, P=0.001. After partial volume 10 
correction, the nucleus basalis of Meynert grey matter mean voxel value remained the only 11 
statistically significant predictor of developing cognitive impairment: [HR]: 0.906, [C.I.]: 12 
0.830–0.991, Wald: 11.447, P=0.003 (Table 4). 13 
 14 
Since previous studies have suggested that University of Pennsylvania smell identification 15 
test (UPSIT), Rapid Eye Movement (REM) Sleep Behavior Disorder Screening 16 
Questionnaire (RBDSQ) assessed REM Sleep Behavior Disorder (RBD), Geriatric 17 
Depression Scale (GDS), Movement Disorder Society sponsored Unified Parkinson Disease 18 
Rating Scale (MDS-UPDRS) Part-III, postural instability, Apo-E genotype group, and 19 
Amyloid-β:Tau ratio could be also predictors of cognitive impairment (Muller et al., 2013; 20 
Schrag et al., 2017), we carried out further bivariate Cox survival analysis to determine 21 
whether nucleus basalis of Meynert grey matter mean voxel value remained a statistically 22 
significant predictor of developing cognitive impairment when adjusting for each of these 23 
variables as covariates in addition to age. We found that nucleus basalis of Meynert grey 24 
matter mean voxel value remained a predictor of cognitive impairment when adjusted for 25 
 14 
UPSIT, RBDSQ, GDS, MDS-UPDRS Part-III, Apo-E, and Amyloid-β:Tau, axial gait score, 1 
and white matter lesions volume (Supplementary Table 2). We then carried out a multivariate 2 
Cox survival analysis with all nine parameters as covariates and further confirmed that 3 
nucleus basalis of Meynert grey matter mean voxel value as a statistically significant 4 
predictor of developing cognitive impairment: [HR]: 0.919, [C.I.]: 0.870–0.971, Wald: 9.211, 5 
P=0.002. As previously indicated by Schrag et al. (2017), we also found UPSIT ([HR]: 6 
0.945, [C.I.]: 0.894–0.999, Wald: 4.014, P=0.045) and Amyloid-β:Tau ([HR]: 202.716, 7 
[C.I.]: 5.870–7000.656, Wald: 8.640, P=0.003) to be significant predictors of cognitive 8 
impairment in the Cox survival analysis with all parameters as co-variates. We further 9 
compared these parameters between the patient groups who developed cognitive impairment 10 
and those who did not. We found increases in scores amongst patients who developed 11 
cognitive impairment in UPSIT, RBDQS, GDS, MDS-UPDRS Part-III, Amyloid-β:Tau ratio, 12 
and axial gait score. There were no differences in Apo-E genotype or white matter lesions 13 
volume (Supplementary Table 3). 14 
 15 
Multivariate Cox survival with the same nine parameters was carried out after partial volume 16 
correction and showed the nucleus basalis of Meynert grey matter mean voxel value as a 17 
significant predictor of cognitive impairment: [HR]: 0.928, [C.I.]: 0.865–0.995, Wald: 4.436, 18 
P=0.035. Similarly, we also found UPSIT ([HR]: 1.175, [C.I.]: 1.007–1.372, Wald: 4.189, 19 
P=0.041) and Amyloid-β:Tau ([HR]: 78.317, [C.I.]: 2.501–2452.692, Wald: 6.158, P=0.013) 20 
to be predictors of cognitive impairment. 21 
 22 
We stratified patients using the average of nucleus basalis of Meynert grey matter mean voxel 23 
values within heathy controls minus one standard deviation (0.278 mean voxel value) and 24 
generated Kaplan-Meier estimates (Figure 3H). The groups had significantly different 25 
 15 
cognitive impairment-free survival times (X2=8.78, P=0.003, 1 degree of freedom) when 1 
compared by a log rank (Mantel-Cox) test. 2 
 3 
Microstructural changes as predictors of Parkinson’s disease cognitive decline. 4 
At multivariate Cox survival analysis of mean diffusivity regions-of-interests and age as a co-5 
variate, we found the nucleus basalis of Meynert mean voxel value ([HR]: 319.587, [C.I.]: 6 
6.830-14954.816, Wald: 8.638, P=0.003) and entorhinal cortex ([HR]: 0.015, [C.I.]: 0.001-7 
0.942, Wald: 3.953, P=0.047) mean voxel value to be statistically significant predictors of 8 
developing cognitive impairment (Table 4). We then carried out a multivariate Cox survival 9 
analysis with all nine parameters as covariates and further confirmed nucleus basalis of 10 
Meynert mean diffusivity mean voxel value as a statistically significant predictor of 11 
developing cognitive impairment: [HR]: 116.445, [C.I.]: 1.085–12497.762, Wald: 3.977, 12 
P=0.046. We carried out further bivariate Cox survival analysis to determine whether nucleus 13 
basalis of Meynert mean diffusivity mean voxel value remained a statistically significant 14 
predictor of developing cognitive impairment when adjusting for each clinical variables and 15 
biomarkers as covariates (in addition to age). We found that nucleus basalis of Meynert mean 16 
diffusivity mean voxel value remained a predictor of cognitive impairment when adjusted for 17 
UPSIT, RBDSQ, GDS, MDS-UPDRS Part-III, Apo-E, and Amyloid-β:Tau, axial gait, and 18 
white matter lesions volume (Supplementary Table 2). After partial volume correction, at 19 
multivariate Cox survival analysis the nucleus basalis of Meynert mean diffusivity mean 20 
voxel value was the only significant predictor of cognitive impairment: [HR]: 11.371, [C.I.]: 21 
1.025-126.172, Wald: 3.920, P=0.048 (Table 4). At multivariate Cox survival analysis of 22 
fractional anisotropy regions-of-interest, no areas were statistically significant predictors of 23 
developing cognitive impairment (positive Level 2 diagnosis) in Parkinson’s disease. 24 
 25 
 16 
We stratified patients using the healthy control mean nucleus basalis of Meynert diffusion 1 
tensor imaging mean diffusivity mean voxel values plus one standard deviation (0.00115 2 
mean voxel value) and generated Kaplan-Meier estimates (Figure 3I). The groups had 3 
significantly different cognitive impairment-free survival times (X2=8.03, P=0.005, 1 degree 4 
of freedom) when compared by a log rank (Mantel-Cox) test.  5 
 6 
Comparison of predictive value between grey and microstructural white matter 7 
data. To identify the better predictor between structural and microstructural changes within 8 
the nucleus basalis of Meynert, we performed a bivariate Cox survival including both mean 9 
diffusivity and grey matter nucleus basalis of Meynert. We found mean diffusivity to be a 10 
statistically significant predictor of cognitive impairment ([HR]: 72.73, [C.I.]: 1.916-11 
2760.399, Wald: 5.338, P=0.021), but not grey matter ([HR]: 0.941, [C.I.]: 0.881-1.006, 12 
Wald: 3.200, P=0.074). 13 
 14 
Axial symptoms and cognitive impairment. We further investigated whether axial gait 15 
is associated with cognitive decline in our population of drug-naïve Parkinson’s disease 16 
patients. In the cross-sectional baseline analysis, we found no difference in axial gait score 17 
(P=0.21). However, at follow-up analysis, cognitively normal Parkinson’s disease patients 18 
who developed cognitive impairment had a higher axial gait score (P=0.02, Supplementary 19 
Table 3). These results were stable after including age as a co-variate in the Cox survival 20 
analysis (HR: 3.144, C.I.: 1.007-9.810, Wald: 3.892, P=0.049). However, in a multivariate 21 
Cox survival analysis including the axial gait score with grey matter nucleus basalis of 22 
Meynert and all nine parameters as covariates, the axial gait score lose its power prediction: 23 
[HR]: 2.255, [C.I.]: 0.493–10.316, Wald: 1.099, P=0.294). 24 
 25 
 17 
White matter lesions volume and cognitive impairment. We investigated whether 1 
white matter lesions volume is associated with cognitive decline. We found no difference in 2 
white matter lesions volume between heathy controls and Parkinson’s disease patients 3 
(t=0.416, P=0.68). In cognitively impaired Parkinson’s disease patients, we found a trend 4 
(not significant) of increased white matter lesions volume compared to cognitively normal 5 
patients (2815.4±2983.7 in PD-MoCA≥26 vs. 3410.9±2980.6 in PD-MoCA≤25; t=-1.48, 6 
P=0.14). At follow-up, cognitively normal Parkinson’s disease patients who developed 7 
cognitive impairment did have only a trend (not significant) of higher white matter lesions 8 
volume (t=-1.51 P=0.14, Supplementary Table 3) compared to patients who did not develop 9 
cognitive impairment. In a Cox survival analysis, we found white matter lesions volume to be 10 
a predictor of developing cognitive impairment in Parkinson’s disease: [HR]: 1.000, [C.I.]: 11 
1.000-1.000, Wald: 6.643, P=0.01. However, when the Cox survival analysis was adjusted 12 
for age as a co-variate, white matter lesions volume lose its power of prediction [HR]: 1.000, 13 
[C.I.]: 1.000-1.000, Wald: 0.821, P=0.365. 14 
 15 
 16 
Assessment of variability between MRI scanners. No regions-of-interest differences in 17 
grey matter mean voxel values were found between T1-MRI data obtained by different 18 
manufacturers (Philips vs. GE. vs. SIEMENS) or strength of field (1.5 vs. 3T). No regions-of-19 
interest differences in mean diffusivity mean voxel values were found between diffusion 20 
tensor imaging data obtained by different diffusion tensor imaging protocols (gated vs. non-21 
gated), or acquired at different centres (Supplementary Table 4 and 5). 22 
 23 
Discussion 24 
 18 
In this study, we set out to prove a hypothesis of a significant relationship between the 1 
damage of cholinergic system and the development of cognitive impairment in Parkinson’s 2 
disease, and demonstrated that microstructural damages of the nucleus basalis of Meynert 3 
underlines and predicts clinical onset of cognitive impairment in Parkinson’s disease.  4 
 5 
We investigated structural and microstructural changes in several brain regions related to 6 
cholinergic system and associated limbic pathways in cognitively impaired compared to 7 
cognitively intact patients with Parkinson’s disease, and relatively to a group of age-matched 8 
heathy controls. We also followed-up cognitively intact Parkinson’s disease patients for 36-9 
months to identify early predictors of cognitive impairment. We used MoCA as a screening 10 
tool for cognitive impairment at baseline, and Level 2 diagnosis also including self-reported 11 
issues in cognitive function, and impairment on at least two cognitive domains at follow-up. 12 
A more sensitive screening tool was beneficial at baseline to look for predictors of cognitive 13 
impairment in all patients with current cognitive impairment or in early developmental stages 14 
of cognitive impairment. Additionally, when looking for predictors of cognitive impairment 15 
in a longitudinal design, we wanted to ensure that predictors were identified before the onset 16 
of clinical cognitive impairment. Therefore, we aimed to exclude all patients who had early 17 
detectable stages of cognitive impairment using this more sensitive test. 18 
 19 
Cross sectional comparison between Parkinson’s disease patients and heathy controls 20 
revealed no differences in grey matter or diffusion tensor imaging mean diffusivity or 21 
fractional anisotropy. Separate subcortical volumetric and microstructural differences were, 22 
however, identified between cognitively normal and cognitively impaired Parkinson’s disease 23 
patients. We found loss of grey matter and increased diffusion tensor imaging mean 24 
diffusivity in the nucleus basalis of Meynert and thalamus of Parkinson’s disease patients 25 
 19 
with cognitive impairment, which indicates damage in these structures. The involvement of 1 
the nucleus basalis of Meynert in cognitive decline in Parkinson’s disease has been described 2 
previously (Gratwicke et al., 2015). Additionally, here, decreased thalamic volume was 3 
observed in Parkinson’s disease patients with cognitive impairment, as suggested by Chen et 4 
al. (2016) who closely associated early cognitive decline in Parkinson’s disease with the 5 
atrophy of the thalamus. These findings demonstrate that changes in both structural (reduced 6 
grey matter voxel mean) and microstructural (increased mean diffusivity) levels in 7 
cholinergic structures underline cognitive impairment in patients with Parkinson’s disease. 8 
Our results were confirmed with region-of-interest and voxel-based analyses, and after 9 
correction for partial volume effects. Interestingly, we found that cognitively impaired 10 
patients had microstructural changes also in the entorhinal cortex (increased mean 11 
diffusivity), but not changes in structural grey matter voxel-based morphometry. The 12 
entorhinal cortex has prominent cholinergic innervation (Heys et al., 2012), and 13 
histopathology has demonstrated that is also affected early by tau pathology (Braak et al., 14 
2006).  15 
 16 
Our longitudinal findings indicated that structural and microstructural changes in the nucleus 17 
basalis of Meynert were predictive for developing cognitive impairment in patients with 18 
Parkinson’s disease. Degeneration of the nucleus basalis of Meynert occurs before the onset 19 
of cognitive impairment, or while cognitive impairment is subclinical. Using Cox survival 20 
analysis, we established that the HR for developing cognitive impairment increases by 9.2% 21 
per every 0.01 decrease in grey matter mean voxel value in the nucleus basalis of Meynert. 22 
We also established that the HR for developing cognitive impairment increases by a factor of 23 
11.4 per every 0.001 increase in diffusion tensor imaging diffusivity mean voxel value in the 24 
nucleus basalis of Meynert. Several studies have suggested indicators of cognitive 25 
 20 
impairment in Parkinson’s disease, and age is widely recognised as a risk factor of cognitive 1 
impairment in both Parkinson’s disease patients and in the general population (Williams-2 
Gray et al., 2013). After adjusting for age in addition to other clinical and non-clinical 3 
indicators of cognitive impairment suggested by Schrag et al. (2017), damage in nucleus 4 
basalis of Meynert remained as a statistically significant indicator of cognitive impairment. 5 
Thereby, we provide further evidence that the degeneration of the nucleus basalis of Meynert 6 
precedes and predicts the onset of cognitive impairment, independently to other clinical and 7 
non-clinical markers of Parkinson’s disease.  8 
 9 
Moreover, our findings show that if both grey matter voxel mean and mean diffusivity of 10 
nucleus basalis of Meynert were included in the same Cox model, mean diffusivity remained 11 
the only predictor of cognitive impairment. This suggests that microstructural changes in the 12 
nucleus basalis of Meynert may precede the structural damage of grey matter measured with 13 
voxel-based morphometry. This is in line with the finding that cognitively impaired patients 14 
at baseline had increased mean diffusivity but normal grey matter voxel mean within the 15 
entorhinal cortex, which is the area with greater connections with nucleus basalis of Meynert. 16 
 17 
Our findings, however, do not indicate when the degeneration of nucleus basalis of Meynert 18 
starts, and how the onset of degeneration relates to the onset of cognitive impairment. Braak 19 
et al. (2003) suggested that Lewy body accumulation of cholinergic neurons in the basal 20 
forebrain occurs at the same stage as the degeneration of dopaminergic neurons in the 21 
substantia nigra pars compacta. This is in line with the finding of Burciu and colleagues 22 
(2017), who found microstructural changes measured in the substantia nigra are key 23 
predictors of motor progression in Parkinson’s disease (Burciu et al., 2017). Taken together 24 
our study with that of Burciu, is possible that measuring the pathological processes at 25 
 21 
microstructural levels with diffusion tensor imaging may be a reliable tool to predict the 1 
development of cognitive decline (measuring the damage of the nucleus basalis of Meynert) 2 
and motor progression (measuring the damage of the substantia nigra) in the early stages of 3 
Parkinson’s disease. Future studies need to clarify this combined predictive value of diffusion 4 
tensor imaging in the same individuals.  5 
 6 
Previous studies have also suggested that white matter lesions are associated with cortical 7 
cholinergic deafferentation in elderly with leukoaraiosis (Bohnen et al., 2009b). White matter 8 
lesions at the frontal horns are in close proximity to cholinergic axons that originate in the 9 
nucleus basalis of Meynert (Bohnen et al., 2009a). Therefore, these lesions may result in 10 
more significant cortical deafferentation because of the more proximal axonal disruption 11 
(Bohnen et al., 2009a). We investigated the presence of white matter lesions (combining T1 12 
and T2-weighted images) and found no differences in cognitively impaired compared to 13 
cognitively normal Parkinson’s disease patients at baseline. In our population, white matter 14 
lesions longitudinally predicted the development of cognitive impairment. However, when 15 
corrected for age, white matter lesions lost their power of prediction, which suggests that the 16 
ageing process more than white matter lesions are associated with cognitive decline. White 17 
matter lesions have also been associated with gait dysfunction, another symptom of 18 
Parkinson’s disease probably related to the damage of cholinergic system (Bohnen and Albin, 19 
2011b). The presence of gait dysfunction and the degree of axial symptoms have been 20 
associated with the development of cognitive impairment in Parkinson’s disease (Bohnen et 21 
al., 2009a; Bohnen and Albin, 2011b; Muller et al., 2013). We investigated the degree of 22 
axial involvement in our population of early Parkinson’s disease patients. We found that 23 
cognitively impaired patients had greater axial gait symptoms compared to cognitively 24 
normal Parkinson’s disease patients at baseline. Axial gait symptoms were predictive of 25 
 22 
cognitive decline when considered alone, but their power as predictors was lower than 1 
diffusion tensor imaging or voxel-based morphometry. Morever, in the full prognostic model 2 
including all the known predictors of cognitive impairment, axial gait symptoms lost their 3 
power of prediction. This may suggest that, in Parkinson’s patients with axial symptoms, the 4 
degeneration of cholinergic nuclei involves not only the pedunculopontine nucleus 5 
(associated with gait dysfunction) but also the nucleus basalis of Meynert. Thus, a damage of 6 
nucleus basalis of Meynert might be a common mediator of the development of cognitive 7 
impairment explaining why most of the studies (that not measured the damage of nucleus 8 
basalis of Meynert) found an association between gait and cognitive decline. 9 
 10 
Our research provides a realistic, cost effective and non-invasive way to identify Parkinson’s 11 
disease patients at higher risk to develop cognitive impairment, before clinical symptomatic 12 
onset. This represents and unmet need; the opportunity to evaluate only one reliable predictor 13 
of cognitive impairment in common clinical practice to allow us to assess patients and stratify 14 
their risk of prodromal cognitive impairment at early stages of the disease, improving patient 15 
care and outcomes(Anang et al., 2017). We provide a clinical tool to screen people in a 16 
routine clinical MRI. We propose that this can further be used by clinicians to assess sub-17 
phenotypes of Parkinson’s disease at higher risk of cognitive impairment as well as to 18 
investigate cognitive impairment and non-motor symptom progression. Clinical trials may 19 
then be tailored on patients at high risk of cognitive impairment, increasing the power of the 20 
analysis for the identification of disease modification treatments.  21 
 22 
In identifying regions-of-interests we used combined probabilistic maps available in 23 
Anatomy Toolbox, a relatively new method. We believe Anatomy Toolbox serves to provide 24 
more accurate regions-of-interest parameters than conventional brain atlases without having 25 
 23 
to manually identify regions and correct for errors. Probabilistic maps accounts for 1 
individuals’ structural differences whilst utilising a standardised mapping format. 2 
Additionally, we acknowledged a limitation of this study to be the difficulty in identifying 3 
cognitive impairment as a prodromal form of Parkinson’s disease dementia, rather than 4 
another form of dementia. To account for this, we distinguished between developing 5 
dementia after Parkinson’s disease, Parkinson’s disease and dementia concurrently, and 6 
dementia preceding Parkinson’s disease by excluding patients screened as cognitively 7 
impaired at baseline for follow up study. This removed patients with dementia preceding 8 
Parkinson’s disease, and Parkinson’s disease and dementia concurrently, which may be 9 
caused by dementia with Lewy Bodies (Bohnen and Albin, 2011a). However, the only 10 
conclusive way of confirming cognitive impairment in Parkinson’s disease as a prodromal 11 
stage of dementia is with a histological post-mortem exam.  12 
 13 
In conclusion, we demonstrated here: (a) that nucleus basalis of Meynert is a predictor of 14 
cognitive impairment in a population of early drug-naïve Parkinson’s patients; (b) that 15 
microstructural changes are stronger predictors compared to structural changes, even after 16 
partial volume correction; (c) that structural changes at voxel-based morphometry and 17 
microstructural changes at diffusion tensor imaging are significant predictor of cognitive 18 
decline also in a model including all the previously suggested predictors (from other studies) 19 
of cognitive impairment in Parkinson’s disease; (d) that white matter lesions are predictors of 20 
cognitive impairment only when ageing in not accounted. As the prevalence of Parkinson’s 21 
disease increases exponentially with age and prevalence of cognitive impairment increases 22 
alongside with the evolution of Parkinson’s disease, a reliable biomarker to identify those 23 
patients at higher risk for cognitive impairment is now more important than ever. 24 
 25 
 24 
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Figure Legends 1 
Figure 1 | Study population. Subjects identified for study (A) Heathy controls and 2 
Parkinson’s disease patients included for grey matter analysis (B) Heathy controls and 3 
Parkinson’s disease patients included for diffusion tensor imaging analysis as fractional 4 
anisotropy and mean diffusivity changes. CI: cognitively impaired; MoCA: Montreal 5 
Cognitive Assessment Scale. 6 
 7 
Figure 2 | A priori regions-of-interests. Anatomy Toolbox regions-of-interests in Montreal 8 
Neurological Institute (MNI) space displayed in coronal (left column) and sagittal (right 9 
column) views. (A) nucleus basalis of Meynert (B) entorhinal cortex (C) amygdala (D) 10 
hippocampus (E) insula (F) thalamus (G) primary somatosensory cortex. 11 
 12 
Figure 3 | (A)–(G) Regions-of-interest grey matter volume of Parkinson’s disease 13 
patients screened at baseline for cognitive function. Patients stratified by cognitive 14 
function using MoCA test (Level 1 diagnosis, Methods). Cognitively normal defined as 15 
MoCA≥25 n=232, cognitively impaired defined as MoCA≤25 n=72. (A)-(G) Individual grey 16 
matter regions-of-interests. Median, 10th, 25th, 75th, and 90th percentile of regions-of-17 
interest mean voxel value shown as box plot. Groups compared by independent samples t-18 
tests, with 302 degrees of freedom (equal variance assumed). Equality of variance tested by 19 
Levene’s test. Statistically significant results indicated by P-values: *P<0.05, **P<0.01. (H) 20 
Cumulative cognitive impairment-free (CI-free) progression amongst Parkinson’s 21 
disease patients stratified by grey matter nucleus basalis of Meynert volume. 232 22 
Parkinson’s disease patients screened as cognitively normal at baseline, at follow up for up to 23 
36 months 35 patients developed clinically confirmed CI (PD-CI) and 197 patients remained 24 
 32 
cognitively normal (PD-noCI). Patients stratified by a split of heathy control mean nucleus 1 
basalis of Meynert grey matter (GM) mean voxel values minus one standard deviation (*) and 2 
Kaplan-Meier graph generated. Log rank (Mantel-Cox) test indicates cumulative 3 
development of cognitive impairment over 36 months are statistically different (X2=8.78, 4 
P=0.003, 1 degree of freedom). (I) Cumulative cognitive impairment-free (CI-free) 5 
progression amongst Parkinson’s disease patients stratified by diffusion tensor imaging  6 
mean diffusivity of the nucleus basalis of Meynert. 34 Parkinson’s disease patients screened 7 
as cognitively normal at baseline, at follow up for up to 36 months 17 patients developed 8 
clinically confirmed cognitive impairment (PD-CI) and 47 patients remained cognitively 9 
normal (PD-noCI). Patients were stratified by a split of heathy control mean nucleus basalis 10 
of Meynert mean diffusivity (MD) mean voxel values plus one standard deviation (*) and 11 
Kaplan-Meier graph generated. Log rank (Mantel-Cox) test indicates cumulative 12 
development of cognitive impairment over 36 months are statistically different (X2=8.03, 13 
P=0.005, 1 degree of freedom). 14 
 15 
Figure 4 | (A) Statistical parametric maps showing reduction in grey matter at voxel-based 16 
analysis cognitively impaired compared to cognitively normal Parkinson’s disease patients 17 
(MNI co-ordinates Nucleus basalis of Meynert, right: x = -4, y = -3, z = -9, left: x = -6, y = -18 
1, z = -9, Thalamus, right: x = 2, y = -13, z = 7, left: x = -2, y = -13, z = 7 and Amygdala 19 
right: x = -30, y = -111, z = -23, left: x = 30, y = -9, z = -23). Yellow–red areas represent 20 
voxel clusters with decreases values within the full brain. P<0.001 uncorr. The colour stripe 21 
indicates z-values. (B) Statistical parametric maps showing increased in mean diffusivity at 22 
voxel-based analysis in cognitively impaired compared to cognitively normal Parkinson’s 23 
disease patients (MNI co-ordinates Nucleus basalis of Meynert, right: x = -6, y = -4, z = -8, 24 
left: x = 6, y = -2, z = -7, Thalamus, right: x = -5, y = -9, z = 1, left: x = 12, y = -21, z = 4, 25 
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Entorhinal cortex, right: x = -21, y = 4, z = -27, left: x = 23, y = 7, z = -26, and Insula, right: x 1 
= -51, y = -17, z = -5, left: x = 48, y = -4, z = -16). Yellow–red areas represent voxel clusters 2 
with increased in MD values within the full brain. P<0.001 uncorr. The colour stripe indicates 3 
z-values. 4 
 5 
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Tables 1 
Table 1. Baseline demographics and clinical characteristics 2 
 Study groups 
 
Heathy controls 
Parkinson’s disease 
patients 
t-test 
Demographic features      
  Sex (female, male) 167 (57, 110) 304 (104, 200) t=0.02 P=0.99 
  Age 59.9 (11.4) 61.4 (9.5) t=-1.49 P=0.14 
  Age of onset - 60.9 (9.5) - 
  Duration of disease - 6.6 (6.6) - 
  PD family history, positive % 4.3 25.3 t=-7.12 P<0.0001 
  Education 16.1 (2.8) 15.5 (2.9) t=2.02 P=0.04 
Clinical characteristics 
  
 
  MDS-UPDRS Part-I 0.6 (1.1) 1.2 (1.5) t=-5.10 P<0.0001 
  MDS-UPDRS Part-I Quest. 2.4 (2.5) 4.3 (3.1) t=-7.12 P<0.0001 
  MDS-UPDRS Part-II 0.4 (0.9) 5.9 (4.2) t=-21.73 P<0.0001 
  MDS-UPDRS Part-III 1.3 (2.7) 20.9 (9.1) t=-34.84 P<0.0001 
  H&Y 0.0 (0.1) 1.6 (0.5) t=-50.79 P<0.0001 
  White matter volume 3107.3 (4837.3) 2956.9 (2988.8) t=0.42 P=0.68 
Non-motor symptom status 
  
 
  GDS 1.4 (2.2) 2.3 (2.4) t=-4.20 P<0.0001 
  SCOPA-AUT 5.7 (3.8) 9.5 (6.2) t=-8.17 P<0.0001 
  ESS 5.7 (3.5) 5.7 (3.4) t=-0.13 P=0.90 
  RBDQS 2.9 (2.3) 4.2 (2.7) t=-5.09 P<0.0001 
  UPSIT 34.1 (4.7) 22.3 (8.3) t=19.80 P<0.0001 
Cognitive status 
  
 
  MoCA 28.3 (1.1) 27.0 (2.2) t=7.84 P<0.0001 
  Semantic Fluency Test 51.6 (11.6) 48.2 (10.7) t=3.15 P=0.002 
  HVLT Immediate Recall 26.0 (4.5) 24.4 (5.0) t=3.42 P=0.001 
  SDM 47.6 (10.7) 41.7 (9.8) t=5.98 P<0.0001 
  Benton JLO 13.2 (2.0) 12.9 (2.1) t=1.77 P=0.008 
MDS-UPDRS: Movement Disorder Society sponsored Unified Parkinson Disease Rating Scale (Part-I, Part-I 3 
Questionnaire, Part-II, and Part-III); H&Y: Hoehn & Yahr scale; GDS: 15-item Geriatric Depression Scale; 4 
SCOPA-AUT: Scales for Outcomes in Parkinson’s disease - Autonomic; ESS: Epworth Sleepiness Scale; 5 
RBDQS: REM Sleep Behavior Disorder Screening Questionnaire; UPSIT: University of Pennsylvania Smell 6 
Identification Test; MoCA: Montreal Cognitive Assessment Scale; HVLT: Hopkin’s Learning Verbal Test; 7 
SDMT Symbol Digit Modalities Test; JLO: Benton Judgement of Line Orientation Test. Tabled values are the 8 
mean of each group with standard deviation in parenthesis (unless indicated otherwise). Age, age of onset, and 9 
education measured in years, duration of disease measured in months. 10 
 11 
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Table 2. Baseline Grey matter and diffusion tensor imaging regions-of-interest volumes between Heathy 1 
controls and Parkinson’s disease patients 2 
 Study groups (mean voxel value) 
 
Heathy controls 
Parkinson’s disease 
patients 
t-test 
Grey matter regions-of-interest volumes 
Nucleus basalis of Meynert 0.361 (0.083) 0.357 (0.089) t=0.39 P=0.69 
Entorhinal cortex 0.530 (0.075) 0.526 (0.081) t=0.54 P=0.59 
Amygdala 0.587 (0.063) 0.587 (0.065) t=-0.08 P=0.94 
Hippocampus 0.492 (0.055) 0.496 (0.059) t=-0.78 P=0.44 
Insula 0.367 (0.056) 0.367 (0.057) t=-0.09 P=0.93 
Thalamus 0.234 (0.035) 0.234 (0.034) t=-0.04 P=0.97 
Primary somatosensory cortex 0.194 (0.050) 0.190 (0.048) t=0.77 P=0.44 
Grey matter regions-of-interest volumes after partial volume correction 
Nucleus basalis of Meynert 0.397 (0.060) 0.392 (0.061) t=0.82 P=0.41 
EC 0.515 (0.062) 0.514 (0.062) t=0.13 P=0.90 
Amygdala 0.514 (0.055) 0.514 (0.055) t=0.07 P=0.95 
Hippocampus 0.449 (0.053) 0.453 (0.053) t=-0.70 P=0.49 
Insula 0.472 (0.057) 0.474 (0.054) t=-0.31 P=0.75 
Thalamus 0.193 (0.028) 0.191 (0.027) t=0.70 P=0.48 
Primary somatosensory cortex 0.291 (0.053) 0.290 (0.050) t=0.16 P=0.87 
Diffusion tensor imaging regions-of-interest fractional anisotropy and mean diffusivity 
Fractional anisotropy    
Nucleus basalis of Meynert 0.450 (0.035) 0.449 (0.034) t=0.13 P=0.89 
  Entorhinal cortex 0.203 (0.017) 0.205 (0.019) t=-0.64 P=0.53 
  Amygdala 0.237 (0.018) 0.237 (0.019) t=-0.03 P=0.98 
  Hippocampus 0.209 (0.021) 0.210 (0.020) t=-0.11 P=0.91 
  Insula 0.223 (0.016) 0.222 (0.014) t=0.34 P=0.73 
  Thalamus 0.313 (0.030) 0.312 (0.025) t=0.08 P=0.94 
  Primary somatosensory cortex 0.151 (0.017) 0.152 (0.017) t=-0.34 P=0.73 
Mean diffusivity*100    
 Nucleus basalis of Meynert 0.124 (0.016) 0.124 (0.015) t=-0.18 P=0.86 
  Entorhinal cortex 0.118 (0.020) 0.118 (0.014) t=0.10 P=0.92 
  Amygdala 0.092 (0.009) 0.092 (0.009) t=0.14 P=0.89 
  Hippocampus 0.113 (0.017) 0.115 (0.021) t=-0.54 P=0.59 
  Insula 0.106 (0.012) 0.108 (0.015) t=-0.70 P=0.49 
  Thalamus 0.096 (0.015) 0.096 (0.017) t=0.01 P=0.99 
  Primary somatosensory cortex 0.105 (0.011) 0.105 (0.011) t=-0.11 P=0.92 
Diffusion tensor imaging regions-of-interest fractional anisotropy and mean diffusivity after partial 
volume correction 
Fractional anisotropy    
  Nucleus basalis of Meynert 0.236 (0.052) 0.236 (0.051) t=0.05 P=0.96 
  Entorhinal cortex 0.173 (0.024) 0.170 (0.019) t=0.69 P=0.49 
  Amygdala 0.219 (0.031) 0.215 (0.025) t=0.72 P=0.47 
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  Hippocampus 0.253 (0.042) 0.250 (0.040) t=0.34 P=0.73 
  Insula 0.220 (0.033) 0.221 (0.027) t=-0.17 P=0.86 
  Thalamus 0.369 (0.033) 0.373 (0.034) t=-0.68 P=0.49 
  Primary somatosensory cortex 0.081 (0.028) 0.084 (0.024) t=-0.81 P=0.42 
Mean diffusivity*100    
  Nucleus basalis of Meynert 0.128 (0.027) 0.130 (0.030) t=-0.32 P=0.75 
  EC 0.106 (0.013) 0.108 (0.012) t=-1.12 P=0.26 
  Amygdala 0.107 (0.012) 0.109 (0.012) t=-1.05 P=0.30 
  Hippocampus 0.112 (0.015) 0.112 (0.017) t=-0.26 P=0.79 
  Insula 0.108 (0.011) 0.112 (0.015) t=-1.69 P=0.09 
  Thalamus 0.123 (0.019) 0.123 (0.020) t=0.01 P=0.99 
  Primary somatosensory cortex 0.079 (0.027) 0.084 (0.028) t=-1.24 P=0.22 
 Tabled values are the mean voxel value of each regions-of-interest with standard deviation in parenthesis. 1 
  2 
 37 
Table 3. Baseline Grey matter and diffusion tensor imaging regions-of-interest volumes between 1 
cognitively intact and cognitively impaired Parkinson’s disease patients 2 
Grey matter regions-of-interest volumes Parkinson’s disease patients 
 Parkinson’s disease subgroups (mean voxel value) 
 PD-MoCA≥26 PD-MoCA≤25 t-test 
Nucleus basalis of Meynert 0.364 (0.087) 0.335 (0.093) t=2.43 P=0.02 
Entorhinal cortex 0.530 (0.077) 0.515 (0.093) t=1.34 P=0.18 
Amygdala 0.592 (0.064) 0.572 (0.067) t=2.30 P=0.02 
Hippocampus 0.500 (0.056) 0.484 (0.065) t=1.98 P=0.05 
Insula 0.370 (0.057) 0.357 (0.056) t=1.79 P=0.07 
Thalamus 0.238 (0.032) 0.223 (0.036) t=3.23 P=0.001 
Primary somatosensory cortex 0.192 (0.048) 0.184 (0.047) t=1.31 P=0.19 
Grey matter regions-of-interest volumes in Parkinson’s disease patients after partial volume correction 
Nucleus basalis of Meynert 0.396 (0.063) 0.377 (0.048) t=2.26 P=0.01 
Entorhinal cortex 0.518 (0.061) 0.503 (0.061) t=1.76 P=0.08 
Amygdala 0.517 (0.055) 0.502 (0.055) t=1.89 P=0.06 
Hippocampus 0.455 (0.052) 0.444 (0.055) t=1.61 P=0.11 
Insula 0.477 (0.055) 0.464 (0.052) t=1.65 P=0.10 
Thalamus 0.194 (0.026) 0.180 (0.028) t=3.74 P<0.001 
Primary somatosensory cortex 0.293 (0.049) 0.280 (0.051) t=1.96 P=0.05 
 Diffusion tensor imaging regions-of-interest fractional anisotropy and mean diffusivity in Parkinson’s 
disease patients 
Fractional anisotropy    
  Nucleus basalis of Meynert 0.451 (0.034) 0.444 (0.035) t=0.83 P=0.41 
  Entorhinal cortex 0.205 (0.020) 0.203 (0.017) t=0.52 P=0.61 
  Amygdala 0.239 (0.020) 0.233 (0.017) t=1.07 P=0.29 
  Hippocampus 0.210 (0.021) 0.207 (0.017) t=0.71 P=0.48 
  Insula 0.224 (0.014) 0.219 (0.012) t=1.37 P=0.18 
  Thalamus 0.314 (0.026) 0.307 (0.024) t=1.05 P=0.30 
  Primary somatosensory cortex 0.153 (0.018) 0.149 (0.016) t=0.85 P=0.40 
Mean diffusivity*100    
  Nucleus basalis of Meynert 0.122 (0.013) 0.132 (0.019) t=-2.30 P=0.03 
  Entorhinal cortex 0.116 (0.013) 0.125 (0.016) t=0.48 P=0.02 
  Amygdala 0.091 (0.007) 0.096 (0.013) t=-1.60 P=0.12 
  Hippocampus 0.111 (0.014) 0.127 (0.032) t=-2.06 P=0.05 
  Insula 0.106 (0.013) 0.115 (0.019) t=-2.34 P=0.02 
  Thalamus 0.093 (0.013) 0.106 (0.024) t=-2.23 P=0.04 
  Primary somatosensory cortex 0.104 (0.011) 0.109 (0.013) t=-1.53 P=0.13 
Diffusion tensor imaging regions-of-interest fractional anisotropy and mean diffusivity in Parkinson’s 
disease patients after partial volume correction 
Fractional anisotropy    
  Nucleus basalis of Meynert 0.235 (0.048) 0.237 (0.061) t=-0.16 P=0.87 
  Entorhinal cortex 0.172 (0.019) 0.165 (0.020) t=1.36 P=0.18 
  Amygdala 0.219 (0.023) 0.205 (0.028) t=2.17 P=0.03 
  Hippocampus 0.256 (0.038) 0.234 (0.044) t=2.17 P=0.03 
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  Insula 0.218 (0.025) 0.231 (0.030) t=-1.98 P=0.05 
  Thalamus 0.379 (0.030) 0.354 (0.042) t=2.91 P=0.005 
  Primary somatosensory cortex 0.083 (0.024) 0.088 (0.025) t=-0.87 P=0.38 
Mean diffusivity*100    
  Nucleus basalis of Meynert 0.125 (0.026) 0.144 (0.037) t=-2.11 P=0.045 
  Entorhinal cortex 0.106 (0.011) 0.115 (0.015) t=-3.20 P=0.002 
  Amygdala 0.106 (0.007) 0.117 (0.018) t=-2.52 P=0.02 
  Hippocampus 0.109 (0.014) 0.124 (0.021) t=-3.68 P<0.001 
  Insula 0.110 (0.015) 0.115 (0.016) t=-1.29 P=0.20 
  Thalamus 0.119 (0.016) 0.135 (0.026) t=-3.38 P=0.001 
  Primary somatosensory cortex 0.082 (0.026) 0.091 (0.032) t=-1.15 P=0.25 
Tabled values are the mean voxel value of each regions-of-interest with standard deviation in parenthesis. 1 
MoCA: Montreal Cognitive Assessment Scale. 2 
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Table 4. Grey matter  and diffusion tensor imaging Predictors of cognitive impairment in Parkinson’s 1 
disease 2 
Grey matter predictors of cognitive impairment in Parkinson’s disease 
  95% C.I.  
 HR Lower Upper Sig. 
Nucleus basalis of Meynert 0.908 0.843 0.978 P=0.01 
Entorhinal cortex 0.939 0.869 1.015 P=0.12 
Amygdala 1.000 0.871 1.148 P=1.00 
Hippocampus 1.081 0.933 1.251 P=0.30 
Insula 1.029 0.933 1.135 P=0.57 
Thalamus 1.011 0.893 1.146 P=0.86 
Grey matter predictors of cognitive impairment in Parkinson’s disease after partial volume correction 
Nucleus basalis of Meynert 0.907 0.830 0.991 P=0.003 
Entorhinal cortex 0.972 0.882 1.071 P=0.56 
Amygdala 1.055 0.885 1.259 P=0.55 
Hippocampus 1.051 0.884 1.249 P=0.58 
Insula 0.955 0.847 1.077 P=0.45 
Thalamus 1.012 0.850 1.204 P=0.89 
Diffusion tensor imaging predictors of cognitive impairment in Parkinson’s disease 
Fractional anisotropy 
  Nucleus basalis of Meynert 1.003 0.985 1.021 P=0.77 
  Entorhinal cortex 1.006 0.985 1.028 P=0.56 
  Amygdala 1.002 0.951 1.056 P=0.94 
  Hippocampus 0.986 0.958 1.014 P=0.33 
  Insula 0.990 0.943 1.038 P=0.67 
  Thalamus 1.010 0.982 1.039 P=0.50 
Mean diffusivity 
  Nucleus basalis of Meynert 319.587 6.830 14954.816 P=0.003 
  Entorhinal cortex 0.015 0.001 0.942 P=0.047 
  Amygdala 7.839 0.002 32627.914 P=0.63 
  Hippocampus 5.294 0.158 177.350 P=0.35 
  Insula 17.892 0.257 1245.817 P=0.18 
  Thalamus 1.042 0.013 84.864 P=0.99 
Diffusion tensor imaging predictors of cognitive impairment in Parkinson’s disease after partial volume 
correction 
Fractional anisotropy 
 Nucleus basalis of Meynert 1.008 0.992 1.024 P=0.33 
  Entorhinal cortex 1.017 0.977 1.058 P=0.41 
  Amygdala 0.964 0.914 1.016 P=0.17 
  Hippocampus 1.007 0.981 1.034 P=0.59 
  Insula 1.003 0.987 1.019 P=0.75 
  Thalamus 0.987 0.957 1.018 P=0.40 
Mean diffusivity 
 Nucleus basalis of Meynert 11.371 1.025 126.172 P=0.048 
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  Entorhinal cortex 1.499 0.004 503.138 P=0.89 
  Amygdala 3.554 <0.001 409.879 P=0.83 
  Hippocampus 0.197 <0.001 87.934 P=0.60 
  Insula 0.959 0.009 97.507 P=0.99 
  Thalamus 1.250 0.002 842.332 P=0.95 
Cox survival proportional hazards analysis of grey matter regions-of-interests mean voxel values. Cox survival 1 
up to 36 months follow up of 232 Parkinson’s disease patients (screened at baseline as cognitively normal): 35 2 
patients developed clinically confirmed cognitive impairment (PD-CI) and 197 patients remained cognitively 3 
normal (PD-noCI). Cox survival proportional hazards analysis of diffusion tensor imaging fractional anisotropy 4 
and mean diffusivity regions-of-interests mean voxel values. Cox survival (backwards: conditional) up to 36 5 
months follow up of 64 Parkinson’s disease patients (screened at baseline as cognitively normal): 17 patients 6 
developed clinically confirmed cognitive impairment (PD-CI) and 47 patients remained cognitively normal (PD-7 
noCI). Hazard ratios (HR) produced with 95% confidence interval (C.I.) and statistical significance (Sig.). Age 8 
is included as a co-variate. 9 
